Physician profile
Mark C Dawson
NPI 1164400867
$2,583.11
in general payments reported to CMS, 2019-2025
31 companies · $186 in 2025
The $186 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $400 · 2021: $305 · 2022: $301 · 2023: $306 · 2024: $426 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $917.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $534.36 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $320.41 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $217.54 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $184.96 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.16 | 2019-2022 | |
| Astellas Pharma US INC | $121.12 | 2019-2021 | |
| Novo Nordisk INC | $100.56 | 2019-2025 | |
| Abbott Laboratories | $95.72 | 2019-2023 | Octrode |
| Gilead Sciences, INC. | $84.23 | 2019-2022 | |
| Cmp Pharma, INC. | $83.79 | 2022 | |
| Janssen Pharmaceuticals, INC | $81.68 | 2019-2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $80.84 | 2019-2023 | Breztri |
| Pfizer INC. | $64.65 | 2020-2024 | |
| Amarin Pharma, INC. | $49.02 | 2019 | |
| Phathom Pharmaceuticals, INC. | $47.87 | 2024 | Voquezna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $44.15 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.94 | 2019-2020 | |
| Inspire Medical Systems, INC. | $30.89 | 2025 | Inspire |
| Mannkind Corporation | $29.26 | 2020-2021 | |
| Ardelyx, INC. | $28.68 | 2024 | Ibsrela |
| Sanofi Pasteur INC. | $27.58 | 2019 | |
| Merck Sharp & Dohme LLC | $26.00 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Otsuka America Pharmaceutical, INC. | $23.13 | 2023 | Nuedexta |
| Exact Sciences Corporation | $22.81 | 2024 | Cologuard Collection Kit |
| Allergan, INC. | $19.82 | 2020 | |
| Corium, LLC | $18.78 | 2022 | |
| Dermira, INC. | $15.70 | 2020 | |
| Insulet Corporation | $15.32 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.94 | 2020 | |
| Dynavax Technologies Corporation | $12.88 | 2023 | Heplisav-B |
| Genentech USA, INC. | $12.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.